Matisse Capital Verona Pharma PLC Transaction History
Matisse Capital
- $184 Million
- Q1 2025
A detailed history of Matisse Capital transactions in Verona Pharma PLC stock. As of the latest transaction made, Matisse Capital holds 13,794 shares of VRNA stock, worth $996,616. This represents 0.47% of its overall portfolio holdings.
Number of Shares
13,794
Previous 14,400
4.21%
Holding current value
$996,616
Previous $668,000
30.99%
% of portfolio
0.47%
Previous 0.35%
Shares
5 transactions
Others Institutions Holding VRNA
# of Institutions
240Shares Held
68.2MCall Options Held
1.41MPut Options Held
299K-
Perceptive Advisors LLC New York, NY6.39MShares$462 Million9.9% of portfolio
-
Nea Management Company, LLC Timonium, MD5.58MShares$403 Million18.53% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$244 Million9.42% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.13MShares$226 Million2.79% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx3.13MShares$226 Million2.81% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $4.4B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...